Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFOX6 Combined With Citrus Flavonoid Tablets (Aimailang) as Neoadjuvant Therapy for Locally Advanced Rectal Cancer With High YWHAB Expression
NCT07176182Phase 2Recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ALIVIAFLEB in rectal cancer (2 arms), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Tumor downstaging rate (to ypTNM stage 0-I). Started Mar 2026; status: recruiting.
02
Drugs
ALIVIAFLEB
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07176182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176182.